Optimistic Investment in Bristol-Myers and Its Growth Potential

This chapter explores the recent enthusiasm for Bristol-Myers stock, driven by promising drug developments like Cobenphie for schizophrenia. The discussion includes sales projections, the company's dividend yield, and a strategy of timing investments with market dips.